Next, we analyzed signaling molecules activated in CD11b cells pulsed with PD-L1 ± CD200AR-L, followed up with in vitro and in vivo effects of CD200AR-L on the expression of PD-1/PD-L1 and CTLA-4. Finally, we analyzed the ability of the CD200AR-L to surmount the suppressive effects of PD-L1.

**Results** Our studies demonstrate that the inhibitory CD200R1 and PD-1 mediate immune checkpoint signaling activities through SHIP1 protein. Moreover, CD200AR-L overpowers the suppressive effects of CD200 and PD-L1, which are both shed by tumors, by downregulating the inhibitory CD200R1 and PD-1 on both antigen-presenting cells (APC) and T-cells (figure 1). In addition, CD200AR-L downregulates PD-1 on APCs and inhibits the upregulation of PD-L1 and CTLA4.

**Conclusions** These studies led to the discovery that this novel peptide modulates the CD200, PD-1/PD-L1 and CTLA-4 pathways, providing the basis for the translatable development of a novel CD200 peptide inhibitor for clinical use against multiple tumors, including gliomas. These studies led to the FDA approval for the first in human peptide checkpoint inhibitor to initiate a phase I single center, open-label, dose-escalation clinical trial in adult patients with recurrent glioblastoma, to be followed by a clinical trial for children with recurrent malignant brain tumors.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0213

---

**Abstract 213 Figure 1** Mechanism of the CD200 Checkpoint Ligand

**Conclusions** These studies led to the discovery that this novel peptide modulates the CD200, PD-1/PD-L1 and CTLA-4 pathways, providing the basis for the translatable development of a novel CD200 peptide inhibitor for clinical use against multiple tumors, including gliomas. These studies led to the FDA approval for the first in human peptide checkpoint inhibitor to initiate a phase I single center, open-label, dose-escalation clinical trial in adult patients with recurrent glioblastoma, to be followed by a clinical trial for children with recurrent malignant brain tumors.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0213

---

**214 THE EFFECT OF ANTI-PD-1 THERAPY ON MEDIAN OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GliOBLASTOMA MULTIFORME PATIENTS WITH CERTAIN TUMOR MARKERS**

Awais Paracha*, Jian Campian, Saint Louis University Medical School, Saint Louis, MO, USA; Washington University, Saint Louis, MO, USA

**Background** Almost 1 in 6 malignant brain cancers are Glioblastoma Multiforme, relative to most other brain cancers it is the most aggressive and prevalent by the numbers. Even with the best treatment options median Overall Survival(OS) remains morbid at 14.6 months and Progression Free Survival (PFS) remains 6.9 months. Telomerase Reverse Transcriptase promoter mutations, Isocitrate Dehydrogenase(IDH) mutations, and Tumor Mutation Burden(TMB) are three prominent tumor markers that are known to be associated with better PFS and OS; markers like these in the presence of new therapies maybe prove crucial to the development of novel therapies. Immunotherapy has been dubbed a ‘game changer’ in certain hematological and solid malignancies. Specifically, PD1 is a glycoprotein that is a strong negative regulator of the immune system, by blocking this glycoprotein Anti-PD-1 agents harness a strong response by the immune system to fight a malignancy. In conjunction with these new found tumor markers, Anti-PD-1 agents maybe the solution that could dramatically improve OS and PFS in these patients.

**Methods** The goal of this study was to retrospectively analyze patients’ charts who had received Anti-PD-1 therapy and had TERT promoter mutations, IDH mutations, different TMBs, and other markers and to compare their OS and PFS outcomes with conventional therapies and their response to immunotherapy.

**Results** Upon analyzing the data the presence of a TERT promoter 124C>T mutation, IDH wildtype, and lower TMB gave much better OS and PFS after treatment in patients on Anti-PD1 therapy.

**Conclusions** Although this was a small study, these results certainly can be used to examine larger subsets of patients with these markers receiving immunotherapy because they had definitively better outcomes as compared to status quo treatment options.

**Ethics Approval** The study was approved by Washington University Ethics Board, approval number 201111001.

**REFERENCES**


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0214

---

**215 AO-176, A HIGHLY DIFFERENTIATED CLINICAL STAGE ANTI-CD47 ANTIBODY, PREFERENTIALLY BINDS TUMOR VERSUS NORMAL CELL CD47 WHEN COMPLEXED TO β1 INTEGRIN**

Robyn Puro*, Prabir Chakraborty, John Richards, Ronald Hiebsch, Michael Donio, W Casey Wilson, Benjamin Capoccia, Carrie Brachmann, Vicki Sugr, Arun Kashyap, Daniel Pereira. Arch Oncology, St. Louis, MO, USA

**Background** Overexpression of CD47 by tumor cells exploits an immune checkpoint preventing tumor recognition and destruction by innate immune cells. Binding of tumor CD47 to SIRPα on macrophages and dendritic cells triggers a ‘don’t eat me’ signal that inhibits phagocytosis and allows escape from innate immune surveillance. Blockade of the CD47/SIRPα axis, however, enables immune recognition and phagocytic clearance of tumor cells. We have developed a clinical stage CD47 targeting antibody AO-176 that is highly differentiated among agents in this class. AO-176 not only blocks the
CD47/SIRPα interaction and induces phagocytosis of tumor cells, but it also has a direct killing mechanism (via PCDIII) and induction of immunogenic cell death, leveraged by preferential binding to tumor versus normal cell CD47.

**Methods** CD47 and β1 integrin expression and localization were evaluated using a combination of flow cytometry, western blotting, confocal microscopy and immunohistochemistry.

**Results** Previously, we described that the preferential binding of AO-176 to tumor versus normal cells was due to its interaction with CD47 molecules that were pre-complexed to β1 integrin. This finding was particularly important and suggestive of why AO-176 does not bind red blood cells since they do not express β1 integrin. We have extended these findings to show that β1 integrin as well as CD47 are also expressed at lower levels in normal versus tumor cells, and that solid and hematologic tumor cells overexpress both CD47 and β1 integrin which correlate with poor prognosis in cancer. In addition, we show that AO-176 is able to bind and occupy CD47/β1 integrin complexes to a greater extent at acidic versus physiologic pH such as would be found in tumor microenvironments, an observation that also contributes to the enhanced targeting of AO-176 to tumor cells. Taken together, these findings add further insight into the preferential binding of AO-176 to tumor versus normal cells.

**Conclusions** The context dependent binding of AO-176 to CD47, when complexed to β1 integrin, is unique among CD47 axis targeting agents and together with its direct killing mechanism of action offers a potentially better safety profile and opportunity for a therapeutic advantage. AO-176 is currently being evaluated in Phase 1 clinical trials for the treatment of patients with select solid tumors (NCT03834948) and multiple myeloma (NCT04445701).

**Trial Registration** NCT03834948, NCT04445701.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0215

---

**216 ANTI-TUMOR ACTIVITY OF IOSH2 BY BLOCKING LILRB2 RECEPTOR SIGNALLING**

Osiris Marroquin Belaunzaran*, Anahita Rafiei, Anil Kumar, Julia Kolibaba, Lorenz Vogt, Sean Smith, Christoph Renner. ImmuOs Therapeutics AG, Schlieren, Switzerland

**Background** The human leukocyte immunoglobulin-like receptor family B (LILRB) acts as checkpoint blockade of the innate immune system by inhibiting leukocyte activation through SHP phosphatase recruitment. Some of the physiological ligands include classical HLA class I molecules, including beta-2-microglobulin (B2M) free open conformers (OC). Natural HLA-OC expression is known from autoimmune disease leading to immune activation by pleiotropic effects since they bind to LILRB and KIR family members reducing Treg and MDSC numbers and increased effector T-cell and NK-cell activation, respectively. We have generated an IgG4-HLA-57 open conformer (OC) molecule (iosH2) with high affinity for LILRB molecules and demonstrate its anti-cancer activity in vitro and in vivo.

**Methods** IosH2 was produced by transient gene expression in CHO cells and purified by standard chromatography. Affinity of iosH2 binding was quantified by ELISA and SPR analysis. HLA-G mediated signaling and competition was assessed using functional cell lines. Effect of iosH2 on activation of SHP1/2 was assessed using Western Blot. Functional assays including in vitro polarization and phagocytosis potential of primary macrophages was assessed by flow cytometry in the presence of iosH2 or isotype control. Effect of iosH2 on T cell activation was evaluated in co-cultures of cancer and T cells. Mouse models were used to assess in vivo activity.

**Results** IosH2 binds to LILRB2 with high affinity and blocks the activation of HLA-G. In addition, iosH2 blocks receptor-mediated signaling of SHP1/2. IosH2 promotes a shift from M2 to M1 macrophages with enhanced tumor cell phagocytosis in vitro. IosH2 enhances activation and killing potential of T cells in cancer cells and T cells co-culture assay. IosH2 exerts therapeutic efficacy in mouse transgenic (melanoma) and different syngeneic tumor models (e.g. pancreatic, colon and breast cancer) as monotherapy. Moreover, it acts synergistically in vivo with PD1 blocking antibodies achieving long-term tumor control. Ex vivo tumor sample analysis demonstrates a significant reduction of MDSC and Tregs and a shift towards an activated inflammatory M1 macrophage phenotype. Loss of MDSC functionality was paralleled by enhanced CD8+ T cell expansion and activity.

**Conclusions** IosH2 binds to LILRB2 with high affinity, restores immune cell function in vitro and demonstrates anti-tumor activity in different in vivo mouse models. In addition, it acts synergistically in vivo with PD1. IosH2 is a first-in-class OC therapeutic with robust anti-tumor activity by promoting key components of the innate immune system. Clinical development is under way and phase I trial in preparation.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0216